Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent ...
Study Results Position Company to Target Segments of $270B+ Multi-Billion Dollar Drug Delivery Systems Market 1 VANCOUVER, BC, Oct. 31, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (BVAXF) ...
Detailed price information for Biovaxys Technology Corp (BVAXF) from The Globe and Mail including charting and trades.
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ...
With an estimated 12,600 new cases of bladder cancer in Canada in 2025, plus almost 84,870 in the United States, ranking 5th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results